Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Frequently asked questions
What sector does Insmed Incorporated (IM8N) operate in?
Insmed Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Insmed Incorporated (IM8N) current stock price?
As of the latest data, Insmed Incorporated stock price is €84.34, with a previous close of €84.34.
What is Insmed Incorporated (IM8N) current market capitalization?
Insmed Incorporated market cap is approximately 18.42 billion.
What is Insmed Incorporated (IM8N) Earnings Per Share (EPS)?
The trailing EPS is -€3.51.
What is Insmed Incorporated (IM8N) EBITDA?
Insmed Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 11.15 million.
Does Insmed Incorporated (IM8N) pay dividends?
No. Insmed Incorporated does not pay a dividend.
When is Insmed Incorporated (IM8N) next earnings report?
Insmed Incorporated is expected to release its next earnings report on September 30, 2026.
What is Insmed Incorporated (IM8N) beta (volatility) score?
Insmed Incorporated has a beta of 0.824, meaning its volatility is roughly in line with the market.
